Trump casts Maduro’s ouster as ‘smart’ move as Russia, China enter the fray
President Donald Trump is taking his pressure campaign to the next level against Venezuelan President Nicolás Maduro and making it...
2026 deadlines loom as Congress leaves DC with several unfinished battles
Capitol Hill is a ghost town with both the House and Senate out of session until a few days into...
Trump suggests he’ll call final shots on peace deal ahead of Zelenskyy meeting: ‘We’ll see what he’s got’
President Donald Trump said he will call the final shots on a peace deal to end the conflict between Russia...
Christmas Eve jazz concert canceled at Kennedy Center after Trump name added to building
A Christmas Eve jazz concert at the Kennedy Center was canceled just days after the White House announced that President...
Here’s how the Cabinet secretaries and their families celebrate the holidays
It’s never a dull moment in Washington during the holiday season — with multiple holiday celebrations at the White House...
Trump-backed candidate Asfura wins Honduras presidential election
Nasry Asfura has won the 2025 Honduras presidential election, delivering victory for the right-of-center National Party of Honduras (PNH) and...
Nearly 20 states sue HHS over declaration to restrict gender transition treatment for minors
A group of 19 Democrat-led states and Washington, D.C., filed a lawsuit against the Trump administration over a declaration that...
DOJ discovers more than 1M potential Epstein records, further delaying file release
The Department of Justice said Wednesday it may have more than a million more documents related to the late Jeffrey...
CORRECTION: Nextech3D.ai Provides Shareholder Update on Krafty Labs Acquisition and Announces $321,917 CEO Investment
Correction: The conversion price was incorrectly reported as .14/share. The correct price is .165/share Correction: Nextech3D.ai Provides Shareholder Update on...
Biotech Market Forecast: Top Trends for Biotech in 2026
The biotech sector is entering 2026 with a positive outlook, characterized by reasonable valuations, robust oncology momentum and supportive policy...